[Infliximab in patients with arthritis psoriatic: systematic review of the clinical and economic literature]
Brodszky V, Pentek M, Gulacsi L
Record ID 32010001762
Hungarian, English
Authors' recommendations:
Clinical efficacy of Infliximab (Remicade) is proved by the available RCTs. There is no significant difference in the efficacy and safety figures of the TNF-alpha inhibitors identified at the use of 5mg/kg Remicade (infliximab) and the regular use of Humira (adalimumab) and Enbrel (etanercept).
Details
Project Status:
Completed
URL for project:
http://hecon.uni-corvinus.hu/download/english/publ/infliximab.hta.AP.2007.december.pdf
Year Published:
2007
URL for published report:
http://hecon.uni-corvinus.hu/download/english/publ/hecon_research_25_eng.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Hungary
MeSH Terms
- Antibodies, Monoclonal
- Antirheumatic Agents
- Review
Contact
Organisation Name:
Unit of Health Economics and Technology Assessment in Health Care
Contact Address:
Unit of Health Economics and Technology Assessment in Health Care Department of Public Policy and Management Budapest University of Economic Studies 1125 Budapest Fovam ter 8 Budapest HUNGARY Tel: +36 1 218 8197 Fax: +36 1 218 1466
Contact Name:
laszlo.gulacsi@uni-corvinus.hu
Contact Email:
laszlo.gulacsi@uni-corvinus.hu
Copyright:
Unit of Health Economics and Technology Assessment in Health Care (HunHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.